Preparation of Luciferin for
In Vitro Bioluminescent Assays
Materials
? D-Luciferin Firefly, potassium salt, 1.0 g /vial
(Caliper Life Sciences Part Number #119222)
? Sterile water
? Complete media
Procedure
1. Prepare a 200X Luciferin stock solution (30 mg/ml) in sterile water. Mix gently by inversion until Luciferin is completely dissolved. Use immediately, or aliquot and freeze at -20 °C for future use.
Note: One can either reconstitute the entire 1.0 g of D- Luciferin in 33.3 mL of sterile water to make the 30 mg/mL (200x) stock solution, or reconstitute the quantity of D-Luciferin necessary for an individual experiment.
2. Prepare a 150 μg/mL working solution of D-Luciferin in pre-warmed tissue culture medium.
Quick thaw 200X stock solution of Luciferin and dilute 1:200 in complete media (150 μg/mL final).
3. Aspirate media from cultured cells.
4. Add 1x Luciferin solution to cells just prior to imaging.
Note: Incubating the cells for a short time at 37 °C before imaging can increase the signal.
Preparation of Luciferin for
In Vivo Bioluminescent Assays
Materials
? D-Luciferin, Firefly, potassium salt, 1.0 g/vial
(Caliper Life Sciences Part Number #119222)
? DPBS, w/o Mg2+ and Ca2+
? Syringe filter, 0.2 um
Procedure
1. Prepare a fresh stock solution of Luciferin at 15mg/mL in DPBS. Filter sterilize through a 0.2 um filter.
2. Inject 10 μL/g of body weight. Each mouse should receive 150 mg Luciferin/kg body weight. (e.g. For a 10 g mouse, inject 100 μL to deliver 1.5 mg of Luciferin.)
3. Inject the Luciferin intra-peritoneally (i.p.) 10-15 minutes before imaging*.
* A Luciferin kinetic study should be performed for each animal model to determine peak signal time.
近日,大眾集團旗下的軟件公司CARIAD中國宣布,與中國頂尖的智能手機制造商vivo共同創建“手車互融聯合創新實驗室”(英文名:MobilexMobilityFusionJointInnovative......
近日,中國科學院大連化學物理研究所生物技術研究部生物分子高效分離與表征研究組研究員趙群、張麗華等,與中國科學院精密測量科學技術創新研究院副研究員龔洲合作,提出了利用原位化學交聯-質譜技術(invivo......
萬物蓬勃的7月里迎來了2022年ANTOP獎的申報和評審工作。由島津企業管理(中國)有限公司申報的“3CoinONE全新體驗氣袋進樣器”ANTOP獎進入專家評審階段。獎項名稱:3CoinONE全新體驗......
青島青源峰達太赫茲科技有限公司研發團隊在國際頂級期刊《TrendsinBiotechnology》(譯名:《生物技術趨勢》)在線發表題為“THzmedicalimaging:frominvitroto......
蛋白質作為構成人體組織器官的支架和主要物質,在人體生命活動中起著重要作用。蛋白質的相互作用能產生許多效應,如形成特異底物作用通道、生成新的結合位點、失活、作用底物專一性和動力學變化等,細胞的代謝、信號......
2021年9月9日,無錫臻和生物科技有限公司(以下簡稱“臻和科技”)與美國VyantBio公司簽署TissueofOrigin?(以下簡稱“TOO?”)全球權益和ZL轉讓協議,全資收購這款唯一獲FDA......
2021年7月20日,JournalofCellularPhysiology及JournalofCellularBiochemistry同時撤回了中國學者49篇文章。從2019年開始,Journalo......
安進宣布,美國FDA授予其在研firstinclass單抗bemarituzumab突破性療法認定,與改良FOLFOX6化療方案(亞葉酸鈣、氟尿嘧啶和奧沙利鉑)聯用,一線治療FGFR2b過表達和HER......
2007年,中國科學院金屬研究所研究員張志東在英國《哲學雜志》(PhilosophicalMagazine)上發表論文,提出兩個猜想,并在猜想基礎上推定出三維伊辛模型的精確解。被《哲學雜志》審稿人評價......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......